– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with ...

BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

Doctors prescribe Briumvi (ublituximab-xiiy) for certain forms of multiple sclerosis (MS). You’ll receive infusions (into your vein) over a period of months. Before each infusion, you’ll receive other ...

In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...